Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

AKT1 (V-akt murine thymoma viral oncogene homolog 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

FoundationOne® CDx (110)

Guardant360® CDx (54)

Oncomine™ Dx Target Test (11)

Oncomine™ Pan-Cancer Cell-Free Assay (4)

TruSight Oncology 500 Assay (3)

Guardant360 TissueNext™ (2)

HTG EdgeSeq Oncology Biomarker Panel (OBP) (2)

Oncomine™ Comprehensive Assay v3M (2)

UW-Oncoplex™ (2)

Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)

Tempus xT Assay (1)

AVENIO Tumor Tissue Expanded Kit

AVENIO ctDNA Expanded Kit

AmoyDx® HANDLE Classic NGS Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer® FusionPlex® Oncology Research Kit

Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit

Archer™ VARIANTPlex™ Complete Solid Tumor panel

Archer™ VARIANTPlex™ Pan Solid Tumor panel

Aventa FusionPlus Test

BROCA Cancer Risk Panel

CNV+ Breast Cancer NGS Panel

HTG EdgeSeq DLBCL Cell of Origin Assay

HTG EdgeSeq DLBCL Cell of Origin Assay EU

Idylla™ PIK3CA-AKT1 Mutation Assay

Ion AmpliSeq Colon and Lung Cancer Research Panel v2

Labcorp® Plasma Complete™

Liquid Trace™ Solid Tumor

LiquidHALLMARK®

NeoLAB® Solid Tumor Liquid Biopsy

NeoTYPE® Lung Tumor Profile

Northstar Select™

NovoFocus™ CRC 2.0

NovoFocus™ NSCLC 2.0 Test

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

OncoPanel™ Assay

Oncomine Focus Assay

Oncomine Precision Assay

Oncomine Solid Tumor DNA Kit

Oncomine Tumor Mutation Load Assay

Oncomine™ Breast cfDNA Assay

Oncomine™ Colon cfDNA Assay

OptiSeq™ Lung Cancer Panel

OptiSeq™ Pan-Cancer Gene Panel

PGDx elio™ plasma resolve assay

PredicineHEME™

RAS-RAF-SEQ Assay

SOPHiA DDM HRD Solution

SOPHiA DDM™ Solid Tumor Plus Solution

SafeSEQ CRC MRD assay

Tempus xF Assay

Tempus xF+ Panel

Tempus xO assay

Theralink Assay

TruSight Tumor 15 Assay

TruSight Tumor 170 Assay

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

oncoReveal™ Solid Tumor v2 Panel

FoundationOne® CDx (110)

Guardant360® CDx (54)

Oncomine™ Dx Target Test (11)

Oncomine™ Pan-Cancer Cell-Free Assay (4)

TruSight Oncology 500 Assay (3)

Guardant360 TissueNext™ (2)

HTG EdgeSeq Oncology Biomarker Panel (OBP) (2)

Oncomine™ Comprehensive Assay v3M (2)

UW-Oncoplex™ (2)

Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)

Tempus xT Assay (1)

AVENIO Tumor Tissue Expanded Kit

AVENIO ctDNA Expanded Kit

AmoyDx® HANDLE Classic NGS Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer® FusionPlex® Oncology Research Kit

Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit

Archer™ VARIANTPlex™ Complete Solid Tumor panel

Archer™ VARIANTPlex™ Pan Solid Tumor panel

Aventa FusionPlus Test

BROCA Cancer Risk Panel

CNV+ Breast Cancer NGS Panel

HTG EdgeSeq DLBCL Cell of Origin Assay

HTG EdgeSeq DLBCL Cell of Origin Assay EU

Idylla™ PIK3CA-AKT1 Mutation Assay

Ion AmpliSeq Colon and Lung Cancer Research Panel v2

Labcorp® Plasma Complete™

Liquid Trace™ Solid Tumor

LiquidHALLMARK®

NeoLAB® Solid Tumor Liquid Biopsy

NeoTYPE® Lung Tumor Profile

Northstar Select™

NovoFocus™ CRC 2.0

NovoFocus™ NSCLC 2.0 Test

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

OncoPanel™ Assay

Oncomine Focus Assay

Oncomine Precision Assay

Oncomine Solid Tumor DNA Kit

Oncomine Tumor Mutation Load Assay

Oncomine™ Breast cfDNA Assay

Oncomine™ Colon cfDNA Assay

OptiSeq™ Lung Cancer Panel

OptiSeq™ Pan-Cancer Gene Panel

PGDx elio™ plasma resolve assay

PredicineHEME™

RAS-RAF-SEQ Assay

SOPHiA DDM HRD Solution

SOPHiA DDM™ Solid Tumor Plus Solution

SafeSEQ CRC MRD assay

Tempus xF Assay

Tempus xF+ Panel

Tempus xO assay

Theralink Assay

TruSight Tumor 15 Assay

TruSight Tumor 170 Assay

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

oncoReveal™ Solid Tumor v2 Panel

›

AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + ER positive	HER2 Negative Breast Cancer	AKT1 mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation	Triple Negative Breast Cancer	AKT1 mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
AKT1 mutation	Colorectal Cancer	AKT1 mutation	Colorectal Cancer	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B
AKT1 mutation	Breast Cancer	AKT1 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
AKT1 mutation + ER positive	Breast Cancer	AKT1 mutation + ER positive	Breast Cancer	capivasertib Sensitive: C1 - Off-label capivasertib Sensitive : C1	capivasertib Sensitive: C1 - Off-label capivasertib Sensitive : C1
AKT1 amplification	Triple Negative Breast Cancer	AKT1 amplification	Triple Negative Breast Cancer	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
AKT1 E17K	Triple Negative Breast Cancer	AKT1 E17K	Triple Negative Breast Cancer	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
AKT1 E17K	Salivary Gland Cancer	AKT1 E17K	Salivary Gland Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 E17K + HR positive	HER2 Negative Breast Cancer	AKT1 E17K + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 E17K	Uterine Leiomyosarcoma	AKT1 E17K	Uterine Leiomyosarcoma	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 mutation + ER negative	Breast Cancer	AKT1 mutation + ER negative	Breast Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3